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Aims: We sought to assess to evaluate the usefulness of SS II in a real-world acute coronary syndromes (ACS)
population with severe coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).
Methods: From August 2011 to May 2013, out of 1591 consecutive patients admitted for ACS, 217 (13.6%) showed
severe CAD (three-vessel disease and/or left main involvement). Among the latter, 100 patients underwent PCI and
were enrolled into the study. SS II was calculated in all patients. One-year clinical follow-up was performed; major
adverse cardiac and cerebrovascular events (MACCE) were defined as a composite of death, nonfatal myocardial
infarction, stroke, or repeat revascularization.
Results: The median SS II was 29 (range, 14–59). Overall, MACCE occurred in 25% of patients (cardiac death 4%,
myocardial infarction 4%, stroke 0%, and repeat revascularization 17%). The 1-year MACCE-free survival was signif-
icantly lower in patients with SS (P29), than in those with SS II (<29) (64.2% vs. 87.2%, respectively; p = 0.007). In
multivariate Cox regression analysis, the presence of unprotected left main stenosis [hazard ratio 2.52, 95% confi-
dence interval (CI): 1.02–5.85; p = 0.031] and SS II P29 (hazard ratio 2.74, 95% CI: 1.30–8.21; p = 0.011) were the only
predictors of MACCE at 1-year clinical follow-up. The c-index of SS score II was 0.70 (95% CI: 0.58–0.81). For patients
who experienced MACCE, the SS II reclassification improved by 36%, while in nonevent patients the reclassification
improved by 22%. The net reclassification index was 0.24 (p = 0.09).
Conclusion: SS II might represent a useful tool to predict clinical events in not only ideal stable patients, but also
an unrestricted, real world population of patients with ACS and severe CAD undergoing PCI.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).he CC BY-
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interventionAbbreviations
ACS acute coronary syndrome
CABG coronary artery bypass grafting
CAD coronary artery disease
CI confidence interval
LVEF left ventricular ejection fraction
LAD left anterior descending
MACCE major adverse cardiac and cerebrovascular
events
MI myocardial infarction
NSTEMI non ST-elevation myocardial infarction
PCI percutaneous coronary intervention
rSS residual Syntax score
SS Syntax score
ST stent thrombosis
STEMI ST elevation myocardial infarction
TLR target lesion revascularization
TVR target vessel revascularization
ULM unprotected left mainIntroduction
The anatomical synergy between percutaneouscoronary intervention (PCI) with taxus and
cardiac surgery (SYNTAX) score (SS) is advocated
in both European and American revascularization
guidelines [1,2] as an important tool that can help
clinicians to establish the optimal revasculariza-
tion approach in patients with complex coronary
artery disease (CAD). The model has also been
proposed as a predictor of clinical outcome follow-
ing PCI [3]. However, it is well recognized that
both anatomical and clinical variables are
required to appropriately stratify the risk of
patients undergoing PCI. Therefore, recent scores
have been developed with the aim of integrating
anatomical features with relevant clinical vari-
ables, to overcome the most obvious pitfalls of a
system score only based on coronary angiograms
[4,5]. Recently, seven clinical parameters [age, cre-
atinine clearance, left ventricular ejection fraction
(LVEF), presence of unprotected left main (ULM),
peripheral vascular disease, female sex, and
chronic obstructive pulmonary disease] have been
added to SS to obtain SYNTAX score II (SS II) [4].
This new score is able to predict a statistically sig-
nificant difference in long-term outcomes between
patients undergoing coronary artery bypass graft
(CABG) and those undergoing PCI [5,6].
However, SS II has been only validated in ran-
domized trials, not in a real-world study; thus,
excluding complex patients such as those with
three-vessel disease and/or ULM involvement,
particularly in the setting of acute coronary syn-
dromes (ACS).
The aim of the current study was to evaluate the
usefulness of SS II in a real-world population with
severe CAD and ACS undergoing PCI.Methods
Study population
From August 2011 to May 2013, all patients
admitted for ACS, at the Cardiology Department
of Cannizzaro Hospital, Catania, were screened.
Those with severe CAD, defined as showing
three-vessel disease (stenosis P70%) and/or left
main involvement (stenosis P50%) at coronary
angiography, with an indication of PCI, were
enrolled into the study. ACSs were definedaccording to the guidelines of the European Soci-
ety of Cardiology [7,8]. Patients with cardiogenic
shock (systolic blood pressure <90 mmHg and
signs of tissue hypoperfusion) and previous
CABG were excluded. All data were prospectively
collected in a dedicated database.
The study was carried out according to the
Helsinki declaration principles, and a written
informed consent to coronary intervention and
follow-up was obtained from all patients.Determination of SS and SS II
From the baseline angiogram, each coronary
lesion causingP50% diameter stenosis in a vessel
with a caliber P1.5 mm, was scored to yield the
overall SS, which was calculated with the SS online
calculator [9]. For each patient, all angiographic
variables involved in the calculation of SS were
computed by two independent experienced inter-
ventional cardiologists blinded to clinical data.
The residual Syntax score (rSS) was calculated
based on the remaining obstructive CAD after
treatment with PCI; incomplete revascularization
was defined as a rSS >0. The D Syntax score
(DSS), representative of the burden of disease
removed by PCI, was calculated by subtracting
the rSS from the baseline SS.
All patients were assessed with echocardiogram
(Philips IE33 Matrix, Philips Healthcare, Amster-
dam, Netherlands), before discharge; and LVEF
was evaluated using a modified Simpson method.
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SYNTAX SCORE II IN COMPLEX PCISTo calculate SS II, the anatomical SS was com-
bined with the following variables: age, creatinine
clearance, LVEF, presence of ULM disease,
peripheral vascular disease, female sex, and
chronic obstructive pulmonary disease; using the
SS II nomogram, as previously described [4].
Procedure and medications
The decision to perform PCI or CABG was taken
by the local heart team, consisting of two interven-
tional cardiologists (not involved in the protocol),
one cardiac surgeon, and one anaesthesiologist.
In case of patient’s refusal to undergo CABG,
PCI was thus considered. According to our routine
practice, staged revascularization was adopted in
all cases: first, PCI of the culprit lesion was per-
formed; then, delayed nonculprit-lesions angio-
plasty before patient discharge, often 3 days to
7 days later. In case of clinical and angiographic
difficulties in distinguishing the culprit vessel,
the different lesions judged to be critical were
simultaneously treated.
During the study period, three types of drug
eluting stents were used: everolimus-eluting
stents (either Xience V, Abbott Vascular, Santa
Clara, California, USA; or Promus, Boston Scien-
tific, Boston, USA), zotarolimus-eluting stents
(Resolute, Medtronic, Minneapolis, Minnesota,
USA), and biodegradable polymer biolimus-
eluting stents (either Nobori, Terumo, Tokyo,
Japan; or BioMatrix Flex, Biosensors Inc., Newport
Beach, California, USA).
PCI treatment was performed by two senior
experienced interventionalists. The interventional
strategy and the use of glycoprotein IIb/IIIaFigure 1. Chart of the study population. ACS = acute coronary syndrome
intervention; ULM = unprotected left main.inhibitors or bivalirudin were entirely left to the
operator’s discretion. For patients who did not
receive bivalirudin, an intravenous bolus of
heparin was given to maintain an activated
clotting time around 250–300 seconds. In addition
to aspirin (300 mg), a loading dose of clopidogrel
600 mg, prasugrel 60 mg, or ticagrelor 180 mg
was administered if the patient was not pre-
treated. Patients were thereafter maintained on
clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor
180 mg for 12 months, and aspirin 100 mg indefi-
nitely. Statin therapy was prescribed in all cases.
Coronary angiograms
Visual coronary angiography analysis was per-
formed by two operators not involved in the pro-
tocol. Angiographic success was defined as a
residual stenosis <20% of the vessel diameter
and thrombolysis in myocardial infarction flow
Grade 3. Procedural success was defined as an
angiographic success in the absence of death,
myocardial infarction (MI), or target lesion
revascularization (TLR) during in-hospital stay.
Complete revascularization was defined as a
restoration of thrombolysis in myocardial infarc-
tion Grade 3 flow with residual stenosis less
<20% on visual assessment in the three coronary
arteries and their major branches (branch diame-
ter >2 mm), with rSS = 0.
Endpoints and definitions
A 1-year follow-up was performed: all patients
were followed-up with telephone interviews;
details about clinical outcomes were confirmed
by reviewing hospital records or by the referring; CABG = coronary artery bypass graft; PCI = percutaneous coronary
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and hospitalizations were prospectively collected.
Major adverse cardiac and cerebrovascular
events (MACCE) were defined as a composite of
death, nonfatal MI, stroke, or repeat revasculariza-
tion. Post-PCI MI and acute MI during follow-up
were defined according to the consensus docu-
ment on the third universal definition of MI [10].
Repeat revascularization included both TLR and
target-vessel revascularization (TVR). TLR wasTable 1. Baseline clinical characteristics of the study population.
Total patients
(n = 100)
Age (y) mean ± SD 66.3 ± 10.6
Men, n (%) 81 (81)
Diabetes mellitus, n (%) 33 (33)
Hypertension, n (%) 59 (59)
Smoke, n (%) 39 (39)
Dyslipidemia, n (%) 77 (77)
Prior MI, n (%) 18 (18)
Prior PCI, n (%) 17 (17)
Chronic kidney disease, n (%) 11 (11)
Peripheral vascular disease, n (%) 10 (10)
COPD, n (%) 9 (9)
LVEF, %, mean ± SD 50.7 ± 7.0
LVEF <50%, n (%) 35 (35)
Clinical presentation
STEMI, n (%) 39 (39)
NSTEMI, n (%) 58 (58)
Unstable angina, n (%) 3 (3)
Dual antiplatelet therapy
Aspirin + clopidogrel, n (%) 33 (33)
Aspirin + prasugrel, n (%) 18 (18)
Aspirin + ticagrelor, n (%) 49 (49)
COPD = chronic obstructive pulmonary disease; LVEF = left ventricular eje
myocardial infarction; PCI = percutaneous coronary intervention; SD = sta
infarction.
Table 2. Angiographic characteristics and procedural details.
Total patient
(n = 100)
Baseline SS, median (ranges) 26 (7–47)
Number of treated vessels, mean ± SD 2.7 ± 0.5
Treated vessels
ULM, n(%) 19 (19)
LAD, n(%) 94 (94)
LCx, n(%) 72 (72)
RCA, n(%) 85 (85)
Number of treated lesions, mean ± SD 3.3 ± 0.9
Number of implanted stents, mean ± SD 3.8 ± 1.4
Total stent length, mm, mean ± SD 86.3 ± 35.7
Complete revascularization, % 67 (67)
DSS, median (ranges) 23.5 (5–46)
Angiographic success, % 100 (100)
Procedural success, % 98 (98)
LAD = left anterior descending; LCx = left circumflex; RCA = right coronary a
left main.defined as repeat PCI or CABG placement for
restenosis at the treated lesions, or occurring
within 5 mm of PCI sites. TVR was defined as a
repeat intervention (percutaneous or surgical) to
treat a luminal stenosis occurring in the coronary
treated vessels beyond the target lesion limits.
Definite/probable stent thrombosis (ST) (acute,
subacute, and late) includes angiographic or
postmortem evidence of ST according to the Aca-
demic Research Consortium recommendations [11].SSII <29
(n = 47)
SS P29
(n = 53)
p
59.8 ± 9.1 72.0 ± 8.5 <0.001
40 (85.1) 41 (77.4) 0.233
17 (36.2) 16 (30.2) 0.336
21 (44.7) 38 (71.7) 0.005
24 (51.1) 15 (28.3) 0.017
35 (74.4) 42 (79.2) 0.371
4 (8.5) 14 (26.4) 0.018
6 (12.7) 11 (20.7) 0.214
0 15 (28.3) <0.001
1 (2.1) 9 (17.0) 0.005
4 (8.5) 5 (9.4) 0.577
52.8 ± 5.2 48.9 ± 7.8 0.005
11 (23.4) 24 (45.3) 0.018
0.196
22 (46.8) 17 (32.1)
23 (48.9) 35 (66.0)
2 (4.1) 1 (1.9)
0.661
14 (29.8) 19 (35.8)
8 (17.0) 10 (18.8)
25 (53.1) 24 (45.3)
ction fraction; MI = myocardial infarction; NSTEMI = non ST-elevation
ndard deviation; SS = Syntax score; STEMI = ST-elevation myocardial
s SSII <29
(n = 47)
SS P29
(n = 53)
p
23 (10–43) 28.5 (7–51) 0.006
2.7 ± 0.4 2.7 ± 0.6 0.889
4 15 0.01
45 (95.7) 49 (92.4) 0.398
39 (82.9) 33 (62.2) 0.02
41 (87.2) 44 (83.0) 0.297
3.4 ± 0.8 3.3 ± 1.0 0.730
4.0 ± 1.3 3.7 ± 1.5 0.322
91.3 ± 33.7 82.0 ± 37.1 0.193
33 (70.2) 34 (64.1) 0.334
18 (5–41) 27 (7–46) 0.007
47 (100) 53 (100) 1
46 (97.8) 52 (98.1) 0.961
rtery; SD = standard deviation; SS = SYNTAX score; ULM = unprotected
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SYNTAX SCORE II IN COMPLEX PCISStatistical analysis
Continuous variables were expressed as
mean ± standard deviations, except SS, SS II,
rSS, and DSS which were expressed as median
and ranges, as they did not follow a normal distri-
bution. One-year clinical outcome analyses were
based on SS median value. Survival analysis
based on Kaplan–Meier curves and log-rank tests
were used to assess the event free-survival
between ACS patients with SS II P29 and ACS
patients with SS II <29. Cox proportional hazardsTable 3. In-hospital and 1-year clinical outcome of the study
population.
Total patients (n = 100)
In-hospital outcome
Death, % 1
Nonfatal MI, % 1
Repeat revascularization, % 0
Stroke, % 0
MACCE, % 2
At 1-year follow-up
Death, % 4
Nonfatal MI, % 4
TLR, % 12
TVR nonTLR, % 5
Repeat revascularisation, % 17
Stroke, % 0
MACCE, % 25
MACCE = major adverse cardiac and cerebrovascular events;
MI = myocardial infarction; TLR = target lesion revascularization;
TVR = target vessel revascularization.
Figure 2. Kaplan–Meier survival curve for major adverse cardiac and c
cardiac and cerebrovascular events; SS II = Syntax score II.regression analysis was applied to identify the
variables associated with MACCE occurrence at
1-year follow-up. All univariate variables with
p < 0.1 were included in the multivariate model.
Discrimination of SS II was tested using c statistic,
while calibration was appraised with Hosmer-
Lemeshow Goodness of fit test. The additive prog-
nostic value of SS II in comparison with SS was
assessed using the net reclassification improve-
ment and the integrated discrimination improve-
ment. In all cases, p values <0.05 were
considered statistically significant. Statistical anal-
ysis was performed with SPSS 21.0 software
(SPSS, Inc., Chicago, IL, USA).Results
Patients’ characteristics and procedural results
Among 1591 consecutive patients admitted for
ACS in our tertiary referral hospital during the
study period, 217 (13.6%) had severe CAD. Among
the latter, 100 patients (46.1%) underwent PCI and
were enrolled into the study (Fig. 1).
The mean age was 66.3 ± 10.6 years; 81% were
men; and diabetes mellitus was observed in 33%
of cases. Baseline clinical characteristics according
to SS II are shown in Table 1. The median of SS
and SS II were 26 (range, 7–47) and 29 (range,
14–59), respectively. Of note, the interobserver
agreement (j statistic) for anatomical SS in our
study was j = 0.88, 95% confidence interval (CI)erebrovascular events at 1-year follow-up. MACCE = major adverse
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commonly revascularized vessel; the number of
treated vessels and lesions were 2.7 ± 0.5 and
3.3 ± 0.9 per patient, respectively. A mean of
3.5 ± 1.4 stents were implanted for a mean total
stent length of 86.3 ± 35.7 mm. Second or third
generation drug eluting stents were employed in
all cases. Angiographic success was achieved in
all patients, while procedural success rate was
98%. Incomplete anatomical revascularization
was obtained in 33% of cases with a median rSS
of 4 (range, 2–18.5). Despite a similar rate of com-
plete revascularization (64.1% vs. 70.2%; p = 0.334),Figure 3. Kaplan–Meier survival curve for cardiac death, myocardial i
II = Syntax score II.DSS was higher in patients with SS II P29, com-
pared with those with SS <29 [27 (range, 7–46)
vs. 18 (range, 5–41), respectively; p = 0.007]. Angio-
graphic characteristics and procedural details are
summarized in Table 2.
Clinical outcome
Overall, at 1-year clinical follow-up, 25% of
patients experienced MACCE. Table 3 shows the
clinical outcome of the study population. A total
of four deaths were observed; all of them were
cardiac deaths. One patient died during the
index hospitalization: he was a 70-year-old mannfarction and for repeat revascularization at 1-year follow-up. SS
Table 4. Univariate and multivariate Cox regression.
Variables HR 95% CI p
Univariate analysis
Age (10 y increase) 1.33 0.93–1.93 0.097
Female gender 1.13 0.42–3.01 0.805
Diabetes 1.46 0.65–3.25 0.355
Chronic kidney disease 2.05 0.97–5.10 0.08
COPD 0.89 0.29–3.55 0.810
Peripheral vascular disease 2.1 1.4.1–6.1 0.01
Prior MI 0.60 0.17–1.95 0.379
Prior PCI 1.38 0.52–3.7 0.515
STEMI 0.85 0.38–1.93 0.701
LVEF <50% 0.83 0.36–1.93 0.672
ULM stenosis 3.2 1.42–7.31 0.005
SS P26a 1.4 0.63–3.12 0.407
SSII P29a 3.3 1.3–8.2 0.011
Incomplete revascularization 0.93 0.40–2.16 0.875
DSS P23.5a 1.6 0.72–3.57 0.245
Multivariate analysis
Age (10 y increase) 1.04 0.56–2.39 0.762
Chronic kidney disease 1.1 0.60–2.72 0.741
Peripheral vascular disease 1.43 0.92–1.87 0.107
ULM stenosis 2.52 1.02–5.85 0.031
SSII P29 2.74 1.30–8.21 0.011
CI = confidence interval; COPD = chronic obstructive pulmonary dis-
ease; HR = hazard ratio; LVEF = left ejection fraction; MI = myocardial
infarction; PCI = percutaneous coronary intervention; SS = Syntax
score; STEMI = ST-elevation myocardial infarction; ULM = unprotected
left main.
a The used cut-off represents the median value of the variable
observed in our cohort.
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SYNTAX SCORE II IN COMPLEX PCISadmitted with an anterior ST-elevation MI (STEMI)
complicated by cardiac arrest due to ventricular
fibrillation. Angiographic analysis showed ULM
thrombosis and right coronary artery chronic total
occlusion. An 87-year-old man with diabetes, pre-
vious MI, and impaired LVEF, who underwent
ULM, left anterior descending (LAD), and left cir-
cumflex PCI, with untreated right coronary artery
chronic total occlusion, had a sudden cardiac
death 3 months after the index PCI. A 75-year-
old diabetic man who underwent ULM, LAD,
and left circumflex PCI, had a fatal acute MI due
to late ST (angiographically demonstrated)
4 months after the index PCI. The last cardiac
death occurred 10 months after the index PCI,
due to MI in an 82-year-old female who under-
went ULM and LAD PCI.
A total of four nonfatal acute MI occurred. One
patient had a troponin I elevation more than five
times the upper reference limit and transient
ischemic electrocardiographic changes immedi-
ately after LAD PCI, with a diagonal occlusion at
control angiogram, medically treated; this patient
was alive and asymptomatic at 1 year follow-up.
The second nonfatal acute MI was a NSTEMI attri-
butable to late ST occurring 2 months after the
index procedure, and successfully treated with
balloon dilatation. The two remaining nonfatal
acute MI occurred both after 10 months from the
index PCI, and were NSTEMI attributable to a
nonpreviously treated small coronary arteries,
managed with medical therapy. Repeat revascu-
larization PCI was performed in 17 patients (12
TLR and 5 TVR nonTLR) after a mean delay of
6.9 ± 2.2 months; while no patient underwent
CABG. Of note, all patients were compliant to
dual antiplatelet therapy during follow-up period;
a switch of P2Y12 receptor antagonist was per-
formed in two patients (one from ticagrelor to
clopidogrel for dyspnea, and one from prasugrel
to clopidogrel for a new onset of AF requiring an
oral anticoagulation).
Patients with incomplete revascularization did
not show worse cardiovascular outcome, com-
pared with those who underwent complete revas-
cularisation (74.6% vs. 75.8%, respectively;
p = 0.554). Similar MACCE rates were also
observed in STE-ACS versus NSTE-ACS patients
either in all cohort (26.2% vs. 23.1%, respectively;
p = 0.398) or in patients’ group of SS II P29
(41.2% vs. 33.3%, respectively; p = 0.398).Figure 4. Receiver operating characteristic curve of Syntax score and
Syntax score II. Area under the curve of SS II was 0.70 (95%
confidence interval: 0.58–0.81), while that of SS was 0.58 (95%
confidence interval: 0.45–0.71) (p = 0.11). SS II = Syntax score II.Prognostic value of SS II
The 1-year MACCE-free survival was signifi-
cantly lower in patients with SSP29 than in thosewith SS <29 (64.2% vs. 87.2%, respectively;
p = 0.007) (Fig. 2). Similarly, the 1-year death-free
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survival (92.5% vs. 100%; p = 0.052) were lower in
patients with SS II P29, as compared with those
with SS <29, with a strong trend. No significant
difference was found regarding repeat
revascularization-free survival between patients
with SSII P29 and those with SS II <29 (79.2%
vs. 87.2%, respectively; p = 0.268) (Fig. 3). In Cox
proportional hazards regression analysis, the
presence of ULM stenosis [hazard ratio (HR)
2.52, 95% CI: 1.02–5.85; p = 0.031) and SS II P29
(HR 2.74, 95% CI: 1.30–8.21; p = 0.011) were the
only predictors of MACCE at 1-year clinical
follow-up (Table 4).
The c-index of SS II was 0.70 (95% CI: 0.58–0.81)
(Fig. 4), and Hosmer-Lemeshow goodness-of-fit
test was p = 0.308. For patients who experienced
MACCE, the SS II reclassification improved by
36%, whereas in nonevent patients the reclassifi-
cation improved by 22%. The net reclassification
index was 0.24 (p = 0.09).Discussion
Our study represents a real world experience of
unrestricted use of PCI to treat complex CAD in
the setting of ACS. We also investigated the ability
of SS II as a new tool to predict clinical outcome at
1-year follow-up.
The main findings of our study can be summa-
rized as follows: (1) PCI in high anatomical and
clinical risk patients admitted for ACS was associ-
ated with high rates of MACCE; and (2) SS II,
combining clinical and anatomical features might
have a prognostic value in such a subset of
patients.
As regards the safety and efficiency of PCI in
high risk patients, it is worth highlighting the high
rate of angiographic success achieved in our
cohort (100%). Moreover, the in-hospital outcome
was uneventful in 98% of cases. In EARLY ACS
trial PCI subgroup, at 96 hours after the index pro-
cedure, Hess et al. [12] showed a rate of cardiac
events as low as 2% (cardiac death 0.4%, MI
1.1%, and ischemia requiring emergent revascu-
larization 0.5%). However, the majority of patients
enrolled in the latter study presented one or two-
vessel disease without ULM involvement [12]. In a
cohort of 903 patients with severe CAD assigned
to PCI, in-hospital MACCE occurred in 4%
patients; notably, PCI was performed in ACS
setting in less than 30% of cases [13]. The
in-hospital outcome of PCI subgroup of the
Multicenter Registry Evaluating Percutaneous
Coronary Intervention Versus Coronary ArteryBypass Grafting for Left Main Treatment (the
Delta registry) showed a MACCE rate of 7.9%
[14]. This latter registry only included patients
with ULM, while this lesion subset was shown in
only 19% of our patients.
In our cohort, repeat revascularization was
required in a relatively high percentage of cases
(17%). Latib et al. [15] and Serruys et al. [13]
reported revascularization rates of 12.7 % and
14.2%, respectively, in such a patients subset after
12 months from the index procedures. In the PCI
subgroup of DELTA registry enrolling patients
with ULM stenosis, TLR at 2-years was 15.5%,
while the overall MACCE was 34.9% [14].
However, achieving complete revascularization
remains challenging in multivessel disease
patients. Despite the relatively high rate of incom-
plete revascularization in our cohort (33%), this
fact was not associated with a higher MACCE rate.
Conversely, Tamburino et al. [16] revealed a
protective effect of complete revascularization at
2-year follow-up for MACE (HR 0.37, 95% CI
0.15–0.92; p = 0.03) and for repeat revascularization
(HR 0.45, 95% CI 0.29–0.69; p < 0.001). Similarly,
Farooq et al [17] demonstrated that rSS was a
powerful indicator of 5-year mortality in the SYN-
TAX Trial. Interestingly in our study, although
higher DSS was achieved in presence of SS II
P29, this subset of patients showed a worse car-
diovascular prognosis. Higher reduction in CAD
burden was not reported to predict a better out-
come [18,19]. This latter finding is in accordance
with a recent report by Witberg et al. [20], who
demonstrated that ‘‘reasonable’’ incomplete
revascularization carries better clinical outcome
versus more aggressive strategy in patients with
three-vessel disease or ULM treated by PCI [20].
However, according to both European and US
guidelines of myocardial revascularization, CABG
remains the gold standard in term of severe CAD
with better long-term outcome [1,21]. Further-
more, in high risk patients such as diabetics, clear
evidence has been demonstrated in favor of
CABG, in the setting of multivessel disease [22].
The decision making process to establish the
optimum revascularization strategy passes
through the concept of ‘‘heart team approach’’
and the evaluation of expected benefits and proce-
dural (interventional or surgical) risk. In this
respect, anatomical SS represents an important
instrument able to predict the outcome of both
strategies; thus, a capital tool to propose the opti-
mal therapeutic method [23]. Indeed, in the
ACUITY trial, the authors showed that the SS is
an independent predictor of the 1-year rates of
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SYNTAX SCORE II IN COMPLEX PCISdeath, cardiac death, MI, and TVR in patients with
NSTE-ACS undergoing PCI [3]. In case of ULM
disease, SS <33 was recognized to have the same
clinical outcomes regardless the adopted strategy,
while a SS P33 goes in favor of CABG; in three-
vessel disease patients, the recommended cut-off
is 23 [1,21].
In addition, the prevailing guidelines advise to
take also into account important clinical variables,
particularly those with an impact on prognosis
[1,2,21,23]. Therefore, scores combining both
anatomical and clinical parameters have emerged.
The SS II has been recently developed by apply-
ing a Cox proportional hazards model to the
results of the SYNTAX trial [4]. This latter score
had a significantly higher accuracy compared with
anatomical SS for all-cause death measured by the
c-statistic [24]. In our study, differently in addition
to the presence of ULM stenosis, SS II was inde-
pendently related to 1-year clinical outcome. Sim-
ilarly, SS II was able to provide reliable
predictions of 4-year mortality for patients with
ULM disease undergoing PCI [4]. At 4-year follow,
according to low-, medium-, and high-risk tertiles,
Campos et al. [6] revealed the following mortality
rates in severe CAD patients who underwent:
95.4%, 88.9%, and 68.1%, respectively. Further-
more, the authors demonstrated that SS II sur-
passed SS in discriminating both CABG and PCI
groups [6].
In a large cohort of 1528 consecutive patients
undergoing ULM PCI, Xu et al. [25] found that
the SS II for PCI was able to risk-stratify patients
and predict long-term adverse ischemic events,
including mortality. Moreover, this scoring system
demonstrated better predictability for long-term
mortality compared with the strictly anatomic SS
among this patients’ subset. Importantly, in the
latter study, a third of patients had a stable angina
[25]. In the setting of ACS, Obeid et al. [26] have
recently demonstrated that SS II provided incre-
mental predictive value for risk stratification,
showing that patients with high SS II (>32) had a
10 and 13-fold high risk for MACE and MACCE,
respectively.
The ultimate objective of the SS II is not only the
isolated risk prediction for PCI or CABG; indeed,
this latter score was developed to evaluate the
interactions of risk factors that could help in the
decision making process between these revascu-
larization strategies. In a patient-level pooled
analysis of a large cohort of patients enrolled in
contemporary coronary stent trials, Compos
et al. [27] demonstrated the capability to help in
stratifying PCI procedures.The originality of our study concerns the fact
that all severe CAD patients enrolled showed
ongoing ischemia. ACS setting is a condition able
to modify some clinical features such as LVEF or
renal function. Indeed, our findings reinforce the
interest of SSII in predicting outcome, surpassing
the anatomical static SS, as it represents a
dynamic risk score able to follow the clinical
presentation.
Study limitations
Our study had some limitations common to the
similar single center studies. First of all is the lim-
ited number of patients. Secondly, the time course
of a clinical tool as SS II was not assessed (i.e.,
changes in creatinine clearance or in LVEF), and
therefore we cannot correlate the occurrence of
major adverse events during the follow-up period
with changes in SS II.Conclusion
As a risk score combining both anatomical and
clinical variables, the SS II might represent a use-
ful tool to predict the risk of adverse clinical
events in not only ideal stable patients, but also
an unrestricted, real-world population of patients
with ACS and severe CAD undergoing PCI.
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